Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said a weaker-than-expected flu season hurt its recent quarter.
Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said a weaker-than-expected flu season hurt its recent quarter.